tagrisso

Frequently asked questions

What does Tagrisso treat?

Tagrisso (Osimertinib Mesylate) may be used to treat non-small-cell lung carcinoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.

How does Tagrisso work?

Tagrisso is a kinase inhibitor. Kinase inhibitors block protein kinases, the enzymes that relay 'grow and divide' signals inside cells. By shutting down the overactive kinase signals that a tumor depends on, they help slow or stop cancer cells from multiplying.

How is Tagrisso rated?

pharmaranks gives Tagrisso a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.

Is there a coupon or discount for Tagrisso?

pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Tagrisso. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.

Who makes Tagrisso?

Tagrisso is marketed by Astrazeneca. You can see Astrazeneca's full profile, rating, and other products on pharmaranks.

Is Tagrisso a brand-name or generic drug?

Tagrisso is a brand-name product with the active ingredient Osimertinib Mesylate.

Is Tagrisso available over the counter?

No. Tagrisso is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.

What forms does Tagrisso come in?

Tagrisso is currently marketed as tablet, per the FDA's National Drug Code Directory.

What class of drug is Tagrisso?

Tagrisso is classified as kinase inhibitor, per the FDA's Established Pharmacologic Class.

Is Tagrisso FDA-registered?

Tagrisso is on record with the U.S. FDA under application number NDA208065. You can verify this on its official FDA label.

Has Tagrisso been recalled by the FDA?

Tagrisso has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.

Is Tagrisso safe?

There's no single safe-or-not verdict. pharmaranks gives Tagrisso a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.